Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy. (Q39788533)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Erb-b2 receptor tyrosine kinase 2

1 reference

1 reference

A Rughetti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

R Landi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

D Pinto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F Bellati

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

H Rahimi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

G P Spinelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

S Pauselli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

V Dolo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F De Lorenzo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F Tomao

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

P Benedetti-Panici

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

L Frati

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Nuti

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Immunopathology and Pharmacology

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

647-658

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

cites work

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Exosome function: from tumor immunology to pathogen biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Malignant effusions and immunogenic tumour-derived exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Tumor-released microvesicles as vehicles of immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Human tumor-derived exosomes down-modulate NKG2D expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Prospects for exosomes in immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Production and characterization of clinical grade exosomes derived from dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Establishment in continuous culture of a new type of lymphocyte from a “burkitt-like” malignant lymphoma (line d.g.-75)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Tumor-Associated Tn-MUC1 Glycoform Is Internalized through the Macrophage Galactose-Type C-Type Lectin and Delivered to the HLA Class I and II Compartments in Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Priming of T cells by exogenous antigen cross-presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200310

10.1177/039463200902200310

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19822081%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference